Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | 18 - 85 |
Updated: | 3/28/2019 |
Start Date: | September 26, 2017 |
End Date: | May 15, 2018 |
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
This is a multicenter, double-blind, placebo-controlled, parallel-design study. The study
will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney
disease and metabolic acidosis. The study dosing (TRC101 or placebo) will continue for 12
weeks once daily.
The maximum study duration is anticipated to be up to 16 weeks.
will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney
disease and metabolic acidosis. The study dosing (TRC101 or placebo) will continue for 12
weeks once daily.
The maximum study duration is anticipated to be up to 16 weeks.
Key Inclusion Criteria:
- Blood bicarbonate level of 12 to 20 mEq/L.
- Estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min/1.73m2.
- Stable kidney function defined as <=20% variability in eGFR during screening period.
Key Exclusion Criteria:
- Any level of low blood bicarbonate during the screening period that in the opinion of
the Investigator, requires emergency intervention or evaluation for an acute acidotic
process.
- Anuria, dialysis, acute kidney injury, or history of acute kidney insufficiency within
3 months prior to screening.
- Heart failure with maximum New York Heart Association (NYHA) Class IV symptoms or that
required hospitalization during the preceding 6 months.
- Heart or kidney transplant.
- Chronic obstructive pulmonary disease (COPD) that is treated with chronic oral
steroids, that requires the subject to be on oxygen, or that required hospitalization
within the previous 6 months.
- Change in doses to alkali therapy in the 4 weeks prior to screening.
- History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing
disorders, inflammatory bowel disease, major gastrointestinal surgery, frequent
diarrhea or active gastric/duodenal ulcers.
- Serum calcium <= 8.0 mg/dL at screening.
- Planned initiation of renal replacement therapy within 12 weeks following
randomization.
- Use of polymeric binder drugs within 14 days prior to screening.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials